

Financial Tearsheet

Company Overview

Kannalife, Inc. is a biopharmaceutical company focused on the development of proprietary and patented cannabidiol (CBD) and CBD-like molecules for patients suffering from unmet medical needs of neurodegenerative disorders - including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE) a disease associated with highly repetitive impact injuries in professional and amateur sports. The Company's family of proprietary molecules focuses on treating oxidative stress-related diseases such as HE, chronic pain from neuropathies like CIPN, and neurodegenerative diseases like CTE. Kannalife conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.

Recent Financial News

Date	Headline
Sep 17, 2020	Kannalife, Inc. Appoints Dr. Tague Honoré as Chairman of the Company's Board of Advisors
Aug 25, 2020	Kannalife, Inc. Receives Patent Grants in Additional European Territories
Jun 30, 2020	Kannalife, Inc. Bolsters IP Portfolio with Multiple Patents Issued in 12 Key European Territories
Jun 02, 2020	Kannalife, Inc. Appoints Terrence O. Tormey to the Company's Board of Advisors
Apr 28, 2020	Kannalife, Inc. CEO Op-Ed Featured in Green Entrepreneur Magazine's Latest Edition

IR Contacts

Investor Relations

Investor Relations Firm
CORE IR
377 Oak Street
Garden City, NY 11530
(516) 222-2285
www.coreir.com
Contact: John Marco
Johnm@coreir.com

Transfer Agent

Securities Transfer Corp.
2901 Dallas Parkway, Suite 380, Plano, TX 75093
(469) 633-0101
www.stctransfer.com

Auditors

DBB McKennon
12790 El Camino Real #130
San Diego, CA 92130
(858) 217-4035
www.dbbmckennon.com
















Corporate Counsel

Procopio, Cory, Hargreaves & Savitch LLP.
525 B Street, Suite 2200
San Diego, CA 92101
(619) 238-1900
www.procopio.com

Stock Performance

Today's Open	0.8000
Volume	1,957
Day Range	0.8000 - 0.8000
52 Week Range	0.3420 - 6.9000
Bid/Ask	0.0000 / 0.8000
Bid/Ask Size	0 X 2,000
Previous Close	0.8000
Market Cap	59.4 million
Shares Outstanding	74.25 million
Dividend/Yield	0.0000 / 0.0000%
EPS (TTM)	-0.057000
P/E Ratio (TTM)	N/A

Recent XBRL Filings

Filing Date ▾	Form Type	Description	View
Aug 12, 2020	10-Q	Quarterly report	  
May 14, 2020	10-Q	Quarterly report	  
Mar 30, 2020	10-K	Annual report	  
Nov 13, 2019	10-Q	Quarterly report	  
Aug 13, 2019	10-Q	Quarterly report	  

Management Team

Dean Petkanas, Chairman & CEO

William A. Kinney, PHD, Chief Scientific Officer

Thoma Kikis, Chief Communications Officer, Board Director

Mark Corrao, Chief Financial Officer

Board of Directors

Dean Petkanas, Chairman & CEO

Thoma Kikis, Founder / Chief Communications Officer, Board Director

Robert Malasek, Director

Blake Schroeder, Director

Timothy Scott, PhD, Director